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5-Dimethylaminopropylamino-8-hydroxytriazoloacridinone (C-1305) is a promising antitumor com-
pound developed in our laboratory. A better understanding of its metabolic transformations is still
needed to explain the multidirectional mechanism of pharmacological action of triazoloacridinone de-
rivatives at all. Thus, the aim of the current work was to predict oxidative pathways of C-1305 that would
reflect its phase I metabolism. The multi-tool analysis of C-1305 metabolism included electrochemical
conversion and in silico sites of metabolism predictions in relation to liver microsomal model. In the
framework of the first approach, an electrochemical cell was coupled on-line to an electrospray ioni-
zation mass spectrometer. The effluent of the electrochemical cell was also injected onto a liquid
chromatography column for the separation of different products formed prior to mass spectrometry
analysis. In silico studies were performed using MetaSite software. Standard microsomal incubation was
employed as a reference procedure. We found that C-1305 underwent electrochemical oxidation pri-
marily on the dialkylaminoalkylamino moiety. An unknown N-dealkylated and hydroxylated C-1305
products have been identified. The electrochemical system was also able to simulate oxygenation re-
actions. Similar pattern of C-1305 metabolism has been predicted using in silico approach. Both proposed
strategies showed high agreement in relation to the generated metabolic products of C-1305. Thus, we
conclude that they can be considered as simple alternatives to enzymatic assays, affording time and cost
efficiency.
© 2020 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tumor diseases are common and usually rapidly progressive
disorders known worldwide [1]. Although current medicine is
developing very dynamically, the possibilities of treating tumors
are still very limited. The success of antitumor therapy with the
chemotherapeutic agent depends on the selection of the medica-
tion characterized by well-balanced profile between efficacy and
safety [2]. In this light, the studies on the possible metabolic
pathways of a potent drug are extremely important for assessing its
bioavailability, activity and toxicity in the human body. InsufficientUniversity.
pean ISSX Meeting (Glasgow,
Meeting (Orlando, FL, USA,
tęga).
on and hosting by Elsevier B.V. Thiknowledge about metabolic transformations of the drug is one of
the most common causes of failure and the lack of complete results
during clinical trials [3].
In recent years the tools for the prediction of metabolic status of
drugs have been developed and improved. The liver microsomal
system is one of the best characterized models for drug biotrans-
formation research which is simple to use [4,5]. This subcellular
fraction contains major drug-metabolizing enzymes, including the
cytochrome P450 (P450) family capable of catalysing the oxidative
biotransformation of most drugs, including antitumor agents, and
other xenobiotics [6]. Thus, the compound incubation with liver
microsomes generates oxidative phase I metabolites. However, the
efficiency of the microsomal approach strongly depends on the
specific expression of different P450 isoforms in each organism.
Consequently, some differences between the metabolites predicted
from liver microsome experiments and the metabolites found in
the patient’s body fluids after the intake of a drug are usually
observed [6,7]. Moreover, a targeted drug may be metabolized ins is an open access article under the CC BY-NC-ND license (http://creativecommons.
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In our studies we considered that in enzymatic metabolism
systems, the processes of purification and separation prior to
identification and quantification of metabolic products are expen-
sive, laborious, and time-consuming [4]. To replace these proced-
ures, other approaches, which are able to support and improve drug
metabolism studies, were developed and they can be classified in
two categories: (i) electrochemical simulation of P450-mediated
reactions and (ii) in silico prediction of drug metabolism. Electro-
chemistry (EC) is one of the classical methods to induce oxidation-
reduction reactions catalyzed by liver P450 isoforms [8,9].
Compared to the enzymatic assays, there are many advantages of
this approach, such as low cost, fast response, simplicity, clean
system, and ease of automation. These are universally valid and
make electrochemical method extremely powerful in drug meta-
bolism studies [10,11]. Nowadays, electrochemical cells coupled on-
line to analytical techniques such as mass spectrometry (MS) with
or without previous liquid chromatographic (LC) separation (Fig. 1)
hold a great potential for simulation experiments and are inten-
sively developed. EC (/LC)/MS techniques may provide exhaustive
information about the properties of the electrochemically gener-
ated transformation products, even though the enzymatic mecha-
nism of transformation differs from the electrochemical oxidative
pathway [9,12,13]. In turn, in silico screening strategy aims at pre-
dicting the most probable sites of metabolism for the investigated
compound, without any need for experimental data. Therefore, this
approach provides the main metabolite structures which can be
formed in various human tissues (liver, skin, brain, and lungs).
Then, the metabolites predicted are listed with a likelihood ranking
[14,15].
The aim of the present research was to investigate C-1305 (5-
dimethylaminopropylamino-8-hydroxytriazoloacridinone) oxida-
tive transformations by the application of three different strategies
for studying drug metabolism: experimental EC, in silico prediction,
and incubation with rat liver microsomes (RLMs). The unknown
products of phase I metabolism were subsequently identified by
using electrospray ionization (ESI) MS.
C-1305 (a structure presented in the frame in Fig. 1) is the most
potent derivative among the antitumor-active triazoloacridinones
developed in our laboratory [16]. It exhibited significant and clearly
differentiated cytotoxicity against a number of tumor cell lines of
human and animal origin in tissue cultures [16,17], as was also
shown in vitro screening scheme (panel of 60 different human
tumor cell lines) in the National Cancer Institute (Bethesda, MD,
USA). Moreover, C-1305 displayed high antitumor potency against
P388 leukemia in mice and towards a wide spectrum of experi-
mental transplantable solid tumors in animals such as colon and
breast cancers [17,18]. C-1305 is the close structural analogue of the
clinically tested imidazoacridinone antitumor agent, C-1311 [19-Fig. 1. Schematic set-up of the system used for the electrochemical generation and ident
antitumor-active triazoloacridinone C-1305 is shown in the frame. LC, liquid chromatograp21]; however, some differences in their chemical structure may
determine the more advantageous pharmacological properties of
the first one. Both compounds were synthesized as a result of
rational drug design strategy based on several circumstances con-
nected with combined characteristics of anthracyclines and acri-
dines essential for biological activity [22,23]. Overall, the specific
structure of C-1305 determines its mode of action that involves
several routes as physicochemical interaction with DNA [24], in-
fluence on cell cycle progression [25], induction of cell death [25],
and others, in particular topoisomerase II inhibition [26,27] and
covalent DNA crosslinking [24]. The leading concept of the anti-
tumor effect of C-1305, similar to the case of C-1311, is considered
as the relationship between its biological activity and the suscep-
tibility to enzymatic oxidation.
The results regarding the capability of the EC to simulate the
oxidative metabolism of C-1305 are discussed here for the first
time. Then, electrochemical findings related to phase I metabolites
of C-1305 were compared with those predicted from in silico
manner and a classical enzymatic approach employing RLMs.
Elucidation of the mechanism of the electrochemical oxidation
would provide a deeper insight into the chemistry and EC of tri-
azoloacridinones. What is more, the identification of the obtained
products would enable their comparison with the C-1305 metab-
olites eliminated from the body. The results obtained from the
proposed multi-tool analysis of C-1305 metabolism would be of
great help in designing new compounds with a better pharmaco-
kinetic profile, or in designing prodrugs where the compound
needs to be metabolized in order to become active.2. Materials and methods
2.1. Chemicals, reagents, and enzymes
C-1305 [16] was synthesized as dihydrochloride in our labora-
tory. The compound was of more than 98% pure as determined by
liquid chromatography (LC) and nuclear magnetic resonance ana-
lyses. The following chemicals were purchased from Sigma-Aldrich
(St. Louis, MO, USA): dipotassium phosphate (K2HPO4), and formic
acid (HCOOH), magnesium chloride anhydrous (MgCl2), monop-
otassium phosphate (KH2PO4) and potassium hydroxide (KOH).
Methanol (CH3OH; gradient grade for LC) and b-nicotinamide
adenine dinucleotide 20-phosphate tetrasodium salt (NADPH) were
obtained from Merck KGaA (Darmstadt, Germany). Ammonium
formate (HCOONH4; reagent grade) was ordered from Fisher Sci-
entific (Loughborough, UK). All other commercially available
chemicals and reagents were of the highest possible grade avail-
able. Ultrapure water of 18 MU･cm of resistivity, used in all the
experiments, was passed through a Milli-Q water purification
system from Merck KGaA (Darmstadt, Germany).ification of C-1305 oxidation products. Molecular structure and atomic numbering of
hy.
Table 1
EC and ESI-MS parameters as applied in direct EC/ESI-MS experiments for deter-
mination of accurate masses of product ions.
A. Potęga et al. / Journal of Pharmaceutical Analysis 10 (2020) 376e384378Pooled RLMs from untreated, male Sprague-Dawley rats (pro-
tein concentration, 20 mg/mL; P450 content, 680 pmol/mg protein)
were purchased from Tebu-bio (Le Perray-En-Yvelines, France).Experiment Parameter Value or setting
EC settings Flow rate 20 mL/min
Potential 0e2.5 V (10 mV steps)
EC operating mode Scan
Cycle Continuous
MS settings Ion source type Dual electrospray
MS operating mode Scan
Ion polarity Positive
The range of m/z 100-1000
Capillary voltage 3500 V
Nebulizer gas (N2) pressure 35 psi
Drying gas (N2) flow 10 L/min
Drying gas temperature 325 C
Fragmentor 175 V
Skimmer 45 V
OCT 1 RF Vpp 750 V
Rate 1.5 spectra/s2.2. Instrumentation
The simulation of the oxidative metabolism of C-1305 was
accomplished in an amperometric electrochemical thin-layer cell
equipped with a disc glassy carbon (GC) working electrode
(4¼ 8mm; A¼ 0.502 cm2) and a Pd/H2 reference electrode (reactor
cell; Antec Leyden, Zoeterwoude, the Netherlands). Carbon-loaded
polytetrafluoroethylene (PTFE) served as auxiliary electrode. The
cell potentials were applied using a ROXY EC System (Antec Ley-
den). All potentials mentioned in this work were based on the
reference electrode. The software used for controlling EC was
Dialogue (Antec Leyden).
The outlet of the electrochemical cell was interfaced into an ESI
source of a quadrupole-time of flight (Q-TOF) mass spectrometer
(Agilent Technologies, Santa Clara, CA, USA) inlet for on-line EC/MS
analysis using PEEK tubing. For controlling the MS, MassHunter
software (Agilent Technology) was used. The electrochemically
generated oxidation products were also off-line injected onto the
LC column, separated, and detected by ESI-MS. LC separations were
performed with Waters Associates HPLC system (Waters Co., Mil-
ford, MA, USA). It was equipped with a model 600 E system
controller, a model 7725i Rheodyne injector, and a model 2996
photodiode array detector (DAD) controlled with Millennium
software (Waters Co.).2.3. Electrochemical simulation of C-1305 oxidative metabolism
The setup used for generation of C-1305 products by electro-
chemical oxidation and subsequent direct (on-line) MS or off-line
LC/MS analysis is shown in Figs. 1, 2, 3, 4, 5 and 6. For electro-
chemical oxidation, 10 mM C-1305 in 0.1% HCOOH in water/CH3OH
electrolyte (50/50, V/V) was conducted through the EC cell using a
dual piston syringe pump model SP2-ROXY (Antec Leyden) at a
flow rate of 20 mL/min. The effluent from the EC was injected
directly into the ESI-MS interface or was collected for further LC/
ESI-MS analysis.2.4. Rat liver microsomal incubations
A mixture of microsomal protein (RLMs) and C-1305, dissolved
in 0.1 M potassium phosphate buffer solution (adjusted to pH 7.4
with 1 M KOH), was pre-warmed for 5 min at 37 C in a shaking
water bath. MgCl2 and NADPH were added to the incubation
mixture (to a total volume of 100 mL), which was then further
incubated for 60 min at 37 C. The final concentrations were as
follows: 2 mg/mL RLMs, 0.2 mM C-1305 (added from 2 mM stock
solution in 0.1 M potassium phosphate buffer solution, pH 7.4),
0.5 mM MgCl2, and 2 mM NADPH (added from 10 mM stock solu-
tion in 0.1 M potassium phosphate buffer solution, pH 7.4). The
incubation was terminated by adding ice-cold CH3OH (1:1, V/V) to
the incubationmixture for the precipitation of proteins. The sample
was then vortexed and placed in ice for 10 min. After centrifugation
at 10,000g for 15 min, an aliquot of the supernatant (150 mL) was
then analysed directly by reversed-phase high-performance LC
(RP-HPLC) with UVeVis detection at 420 nm and/or diode array and
multiple wavelength detection, and monitored by MS. For each
incubation, a negative control was carried out without the cofactor
NADPH to prevent P450 catalysis. All assays were conducted in at
least triplicate.2.5. In silico prediction of C-1305 metabolism in liver
The MetaSite software tool (version 5.1.1; Molecular Discovery
Ltd., Hertfordshire, UK) is a computational algorithm that predicts
the most likely metabolic transformations of the compound related
to phase I reactions in the liver. Moreover, it provides the structure
of the metabolites, formed with a ranking derived from the site of
metabolism predictions, with exact molecular weight (MW) and
calculated logarithm of partition coefficient (cLogP) to help and
complement the experimental elucidation of metabolite structures.
A 2-D structure of the C-1305 was imported into the interface of
MetaSite to predict metabolic soft spots for liver metabolism and
structures of metabolites in the liver related to P450-mediated
reactions. Only metabolites with a molecular mass higher than
150 Da and with a likelihood ranking 50% were considered.
2.6. EC and ESI-MS conditions
ESI-MS detection of C-1305 products generated by EC was per-
formed in the positive ion mode in the full scan mode (mass-to-
charge ratio, m/z 100-1000). The detailed EC and ESI-MS parame-
ters are presented in Tables 1 and 2.
2.7. LC conditions
Chromatographic separations of the parent drug and its trans-
formation products were carried out using a reversed-phase 5-mm
Suplex pKb-100 analytical column (C18) (Supelco Inc., Bellefonte,
PA, USA) with the following dimensions: 250 mm length  4.6 mm
i.d., 5-mm particle size. The column was operated at a room tem-
perature of 25 C. The flow rate utilized was 1 mL/min. For all
chromatographic separations, eluent A of the mobile phase was a
solution of 0.05 M HCOONH4 in water (adjusted to pH 3.4 with
HCOOH). Eluent B was CH3OH. A linear gradient from 15% to 85% B
in A was kept for 25 min, then followed by a linear gradient from
80% to 100% B in A for 3min. A rate of 100% of solvent B was kept for
1.5 min before returning to initial conditions within 0.5 min. These
were then kept for 10 min to allow for column equilibration.
3. Results and discussion
Any drug development process must proceed through several
stages in order to produce a product that is efficacious and safe.
Hence, one of the most important topics is identifying metabolic
Fig. 2. The representative MS spectrum of C-1305 (m/z 338) before (reactor cell off; the
inset at the top-left corner) and after (reactor cell on) reaction in the electrochemical
cell (positive-ion mode).
Fig. 3. The representative ion mass intensity-time curves of 10 mM C-1305 oxidation at
a GC working electrode (positive-ion mode). The m/z ratios shown correspond to the
protonated [MþH]þ C-1305 and its oxidation products (see legend). The signal is
dependent on the voltage used in the EC cell (two and half cell cycles are shown).
Experimental conditions: potential range 0e2.5 V; scan rate 10 mV/s, continuous;
T ¼ 21 C; 4 GC working electrode 8 mm.
Fig. 4. The representative EICs of C-1305 and its oxidation products found in an
electrochemical simulation (EC) (A) and in an incubation mixture with rat liver mi-
crosomes (RLMs) (B). The m/z ratios shown correspond to the protonated [MþH]þ C-
1305 and its oxidation products. Peak names correspond to compounds presented in
Table 2.
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the generation and characterization of various types of drug me-
tabolites that determine its bioavailability, activity and toxicity
profile in humans. In this work, three different strategies for the
investigation of C-1305 oxidative metabolism were used. In the
following part, the results of electrochemical simulation are dis-
cussed towards their correlation with the results from a conven-
tional microsomal experiment and in silicomodel for the prediction
of potential liver metabolism reactions. The C-1305 products of
electrochemical and enzymatic transformations were separated
and analysed by RP-HPLC with UVeVis detection and/or diode
array and multiple wavelength detection. For structure elucidation
of the detected compounds, ESI-MS experiments were performed.
3.1. Electrochemical generation of C-1305 oxidation products
The focus of this study lied in the investigation of the metabolic
pathway of C-1305 using the purely instrumental EC method. Nometabolism data for this compound is yet available from such a
matrix-free environment. In the beginning, in order to obtain a
comprehensive overview of C-1305 oxidation products, the elec-
trochemical method was optimized by adjusting several parame-
ters. The obtained results (Tables S1 and S2) indicated that type of
electrolyte (composition, pH), working electrode material, flow
rate, and potential range influenced the number and/or amounts of
products formed during the electrochemical treatment. Finally, the
highest electrochemical conversion of C-1305 into its expected
products was achieved for 0.1% HCOOH inwater/CH3OH electrolyte
(50:50, V/V) with a flow rate of 20 mL/min and with GC as working
electrode material operated in the range of potential 0e2.5 V. GC
electrode, widely used in EC, can be applied over an extended po-
tential range when oxidation reactions occur. Thus, due to its high
overpotential for oxygen, it cannot be excluded that partial elec-
trolysis of the aqueous solvent also took place. The working elec-
trode surface was cleaned between each oxidation step by flushing
with a solution of 50% CH3OH in water. When disassembling the
working electrode after an oxidation, no adsorption residue was
visible.
In order to obtain products generated electrochemically from C-
1305, the parent compound was introduced into the electro-
chemical cell at a flow rate of 20 mL/min for a designated time
period. The scanmodewas used for continuous synthesis of C-1305
Table 2
Molecular formulas of C-1305 and its products found after electrochemical oxidation on a GC working electrode in a potential range of 0e2.5 V versus Pd/H2 and predicted in
incubations with RLMs or by MetaSite. The structural calculations are based on exact masses, with the relative mass deviations between measured and theoretical m/z values













C-1305 16.46 338.1608 C18H19N5O2 1.0 - -
P1 10.08 366.1546 C19H19N5O3 4.0 þ O - 2H þ CH2 (oxidation þ methylation) EC
P2 11.76 382.1512 C19H19N5O4 0.6 þ CO2 (carboxylation) EC
P3a,b 11.85, 14.52 352.1392 C18H17N5O3 3.4 þ O - 2H (oxidation) EC, RLMs
P4 15.90 368.1703 C19H21N5O3 3.8 þ O þ CH2 (hydroxylation þ methylation) EC
P5 16.38 310.12984 C16H15N5O2 1.6 - 2CH2 (N-demethylation) EC, RLMs
P6a, b 16.52, 17.97 354.1550 C18H19N5O3 3.0 þ O (hydroxylation/N-oxidation) EC, RLMs, MetaSite
P7 NDb 324.1442 C17H17N5O2 4.0 - CH2 (N-demethylation) EC, MetaSite
a Exact masses were calculated using Molecular Mass Calculator freeware version v2.02.
b ND, not detected.
A. Potęga et al. / Journal of Pharmaceutical Analysis 10 (2020) 376e384380oxidation products. Fig. 2 illustrates the MS spectra of C-1305
before (cell off, control measurement; Fig. 2 inset) and after (cell
on) reaction in the electrochemical cell. When the potential was not
applied to the EC system, the MS spectrum shows the peak at m/z
338, that is attributed to the C-1305 ion [MþH]þ. Additionally, in a
solution of C-1305 without electrochemical oxidation, we also
observed an intense ion at m/z 310 which might correspond to C-
1305 derivative. In turn, the intensity of these peaks decreased with
the increasing potential and depended on the potential value the
peaks of the appropriate oxidation products appeared. The ob-
tained results were displayed as ion mass intensity-time curves,
which made it possible to perform fast screening for electro-
chemically generated products by showing the ion signal intensity
of the relevant product (y-axis) depending on the time of the
electrochemical conversion (x-axis) (Fig. 3), which reflected the
changes in electrochemical potential. After electrochemical reac-
tion seven possible products of C-1305 were detected. A growth in
the intensity of signals coming from oxidation products and a drop
in the intensity of signal from parent ion were observed.3.2. Separation and identification of the electrochemical products of
C-1305
For characterization of C-1305 electrochemical products inmore
detail regarding their polarity, a separation method based on RP-
HPLC has been developed. The extracted ion chromatograms
(EICs) of C-1305 and its generated electrochemically potential
products are shown in Fig. 4A. These datawere then comparedwith
LC/ESI-MS data obtained from liver microsomal incubation. With
the application of off-line EC RP-HPLC/ESI-MS method, C-1305 and
its six electrochemical products were identified. Table 2 provides a
list of the products of electrochemical conversion of C-1305 char-
acterized by different m/z values, retention time and the proposed
transformations of C-1305 molecule. The deviation of measured m/
z to the theoretical m/z, given as relative mass deviation (ppm) ¼
((m/zexperimental e m/zcalculated)/m/zcalculated)  106, was for all
products  4 ppm.
P450 is the most important enzyme system that catalyses a
variety of oxidative transformations of xenobiotics and endogenous
compounds (phase I reactions). P450s activate molecular oxygen
and transfer a single oxygen atom to a substrate while the other
oxygen atom ends up inwater molecule [28]. These oxygen transfer
reactions include the following: aromatic/aliphatic hydroxylations,
epoxidation, and heteroatom oxidations. Additionally, P450s can
also promote heteroatom-dealkylations, dehalogenation, and
dehydrogenation [29]. As can be seen from the literature, the
electrochemical system is able to successfully simulate the majority
of P450-catalyzed mixed-function oxidation reactions [9-13].During the direct electrochemical oxidations, the electrode behaves
as an oxidant which can be adjusted by the applied potential in
order to perform charge transfer reactions [8]. The proposed elec-
trochemical conversion of the investigated triazoloacridinone,
summarised in the reaction scheme shown in Fig. 5, includes
mainly N-dealkylation (P5 at m/z 310 and P7 atm/z 324) and single
O gain via hydroxylation (P6 at m/z 354).
N-Dealkylation is a typical biotransformation pathway in P450-
catalyzed oxidation reactions that usually inactivates xenobiotics,
including secondary and tertiary amines found in many drugs, and
facilitates their elimination [30]. It can be readily simulated by the
EC system. The electrochemical mechanism resembles to a large
extent a single-electron transfer mechanism mediated by P450. It
consists of an initial electron abstraction, followed by deprotona-
tion and the subsequent abstraction of another electron that results
in an iminium intermediate. Following hydrolysis, the intermediate
decomposes into the final N-dealkylated product [31]. In the case of
C-1305, N-demethylated and N-bis-demethylated products were
obtained in the electrochemical cell. The chromatographic peak of
the latter (P5, m/z 310) was eluted with the peak corresponding to
that of substrate (C-1305, m/z 338), which indicates that these
compounds may have similar polarity. In turn, product P7, which
had been previously found in EC analysis, was not detected after
chromatographic separation, likely due to the slightly inferior limit
of detection and/or its limited chemical stability. It should be noted
that reactive iminium intermediate formed during N-dealkylation
process may be associated with the mechanism-based inactivation
of P450 enzymes reported for C-1305 [32].
Another remarkable oxidative capability of P450 is hydroxyl-
ation [30]. This process can be easily induced electrochemically at
positive potentials [12]. The presence of an ion at m/z 354 corre-
sponding to an increase in mass by 16 Da confirmed that successful
electrochemical hydroxylation of C-1305 molecule took place.
Further, two different isomers of this product (peaks P6a and P6b in
Fig. 4A) were found after chromatographic separation of the post-
electrochemical mixture. Both are characterized by retention time
slightly higher than that of C-1305.
Due to the presence of an additional hydroxyl group there may
be more polar substances than substrate. Therefore, it is suspected
that O gain might have occurred at various positions of the C-1305
molecule by aliphatic and aromatic hydroxylation. The electro-
chemical oxidation potentials for hydroxylation of aliphatic C-H
bonds are generally very high [12], but the application of a potential
of above 2 Vmight have enabled oxidation reaction in this case. We
suppose that the product of such hydroxylation was obtained with
lower yield. For product P6, a putative structure of diol (quinol) is
also considered. Electrochemical oxidation of aromatic ring is
initiated by electron abstraction. This electron transfer requires a
Fig. 5. Overview about all relevant products generated after electrochemical oxidation of C-1305 with proposed structure. Observed m/z value is shown. Numbers correspond to
compounds presented in Table 2.
A. Potęga et al. / Journal of Pharmaceutical Analysis 10 (2020) 376e384 381lower positive potential than for aliphatic hydrocarbons due to
resonance stabilization of the aromatic radical cation. In order to be
oxidized electrochemically within the potential limits of water, the
aromatic ring must be activated by an electron-donating group.
This requirement was made by 8-hydroxyl group present in the
triazoloacridinone moiety. It can be expected that analogously as
for compound C-1311 [33], the activation of the triazoloacridinone
ring system at position ortho to this functional group will be the
most preferential. Furthermore, product P3 observed at m/z 352,
indicating the mass gain of two hydrogens, was very likely gener-
ated from product P6 by dehydrogenation. Thus, the above hy-
droxylations might have proceed immediately to respective less
polar carbonyl or quinone derivatives.
In our study we also observed signals at m/z 366 (P1), 368 (P4),
and 382 (P2) which could be supposed to be the potential products
resulting from the combination of different oxidative pathways
(e.g., hydroxylation, dehydrogenation) of the investigated anti-
tumor agent. In the elution profile their peaks appeared before the
C-1305 peak. When considering the structure of the product P4, it
can be assumed that the addition of a single methoxy group ach-
ieved by EC could have taken place here. We found that its for-
mation was highly dependent on the electrolyte used. So, it is
suggested that this product may result from the interaction be-
tween the substrate to be oxidized and CH3OH being a component
of the electrolyte solution.3.3. Metabolism study in RLMs
In order to obtain the metabolite profiling of drug compounds,
the incubationwith livermicrosomes is a conventional, well known
method [4,5]. Therefore, this approach was performed on C-1305 to
compare the metabolic products with those detected after elec-
trochemical conversion of the studied compound. The represen-
tative EICs of C-1305 products obtained from microsomal
incubations are shown in Fig. 4B. In the sample taken from rat liver
microsomal incubation with C-1305, compared to the purely
instrumental non-enzymatic approach, the presence of only three
metabolites of the parent drug: C-1305 þ O - 2H (peak P*3a at m/
z ¼ 352), C-1305 - 2CH2 (peak P*5 at m/z ¼ 310), and C-1305 þ O
(peak P*6a at m/z ¼ 354) was observed. No additional metabolites
were detected in the LC/ESI-MS analysis of the microsomal sample.
Although liver microsomes contain the physiologically relevantcombinations of drug-metabolizing enzymes, the expression of the
different P450 isoforms may be very diverse in each organism. This
may explain why some products of C-1305 generated electro-
chemically were not produced in liver microsomes.
The peaks of products P*3b, P*5, and P*6b were characterized
by retention time identical to that of products P3a, P5, and P6b from
EC analysis. The first two were of low intensities, whereas the
amount of this latter increased with longer incubation time. Based
on the experimental mass ion data, the same observations as for the
previously identified products of electrochemical conversion were
made for the P3a and P5 structures. Thus, N-dealkylation of alkyl-
amine, hydroxylation and dehydrogenation seem to be the main
pathways in both EC and enzymatic oxidations of C-1305. The
generation of metabolite P*b presumably involves the insertion of a
single oxygen atom that, as it was proposed above, may take place
under the formation of a hydroxyl group. However, the antitumor
agent selected for this study was a good substrate for human re-
combinant flavin-containing monooxygenases (FMOs), FMO1 and
FMO3 [34]. FMOs can oxidize a wide array of heteroatoms, partic-
ularly soft nucleophiles, such as amines, in the presence of an ox-
ygen, an NADPH cofactor, and an FAD prosthetic group [35].
Assuming that the active enzymes of RLMs are FMOs, it was sug-
gested that peak P*6b at m/z 354 may be an amine-N-oxide. Ni-
trogen oxidation is also possible in the EC system, but unlike
formation of S- or P-oxides, N-oxide formation can only be detected
in low yields [12,36].3.4. In silico prediction of C-1305 liver metabolism
MetaSite software allowed to predict the main sites of liver
metabolism for C-1305 and its main metabolic reactions (Fig. 6).
The most probable sites of P450 attack in the C-1305 molecule
proved the dialkylaminoalkylamino moiety and the carbon atom at
position 9 of the triazoloacridinone ring. In view of this, five top
ranked phase I metabolite structures were reported.
One of the major metabolites predicted was that derived by the
cleavage of the N-C bond leading to N-demethylation (M1; 100% of
likelihood). The identical product ion P7 at m/z 324 was also
identified by EC/ESI-MS analysis. In turn, further degradation of the
side chain may result in a complete N-dealkylated metabolite M4
(50% of likelihood) which, in contrast to M1, was not generated
from electrochemical oxidation. Another metabolic reaction
A. Potęga et al. / Journal of Pharmaceutical Analysis 10 (2020) 376e384382predicted for C-1305, common to the P450 catalytic activity, was
also dehydrogenation in the propylamino chain (M5; 50% of like-
lihood). The N-dealkylation and dehydrogenation reactions in the
dialkylaminoalkylamino side chain, analogous to those described
above, were also predicted by in silico analysis for imidazoacridi-
none derivative, C-1311 [37]. Such substituent is flexible and, after
metabolic activation, it may be able to induce interstrand covalent
crosslinks in DNA of tumor cells playing a key role in biological
(antitumor) activity of these compounds [24,38,39]. Such mecha-
nism mediating the cytotoxicity was also demonstrated in the case
of the clinically used antitumor drugs, mitoxantrone and ametan-
trone [22]. Further, MetaSite indicated the possibility of the for-
mation of two isomeric hydroxylated metabolites (MW ¼ 353.15)
with various ranking that can be linked with product ion P6 at m/z
354 found after electrochemical simulation. The most probable
hydroxylation site in the C-1305 molecule appears to be the ortho
position to the hydroxyl group in the aromatic ring, giving
metabolite M2 (66% of likelihood). The resulting diol (quinol) and
its putative quinone derivative, which may correspond to product
ion P3 obtained at m/z 352 in the EC analysis, are the preffered
structures for the substitution by nucleophiles existing in a living
organism (i.e., reduced glutathione, thiols of proteins or purine and
pyrimidine bases of DNA). The formation of stable adducts may
alter biological functions of cellular biomolecules, which ultimately
leads to a toxic response [5]. Thus, both diol and quinone metab-
olites may be responsible for cytotoxic and antitumor actions of
triazoloacridinones. Moreover, they may be related to the observed
inactivation of P450 1A2 and 3A4 by C-1305 by the covalentFig. 6. Liver metabolism prediction by MetaSite for C-1305. Ranking of the metabolites (A)
(50% of likelihood) (B). The functional groups in compound that most likely will be meta
marked functional group e the higher the probability of metabolism to occur. MW and cL
Discovery Ltd., Hertfordshire, UK). MW, molecular weight; cLogP, the logarithm of partitionapoprotein modification of P450 isoenzymes [32]. In addition to
aromatic hydroxylation, aliphatic hydroxylation is also possible, as
in the case of metabolite M3 (50% of likelihood).
The ability of the drugs to penetrate various biological mem-
branes, tissues and barriers is determined by the hydrophilic or
hydrophobic properties of molecules, for which the partition co-
efficient, P, of a molecule is used [40,41]. In the case of all MetaSite
predicted metabolites of C-1305 formed by liver P450s, the calcu-
lated cLogP values were in the range of 0.90e1.88. It means that
they are rather more hydrophilic substances than the parent
compound (cLogP ¼ 2.06), so they may be preferentially localized
in hydrophilic compartments, such as blood serum, and easily
excreted from the body.
To sum up, in silico study has demonstrated the possibility to
theoretically predict the main metabolites of antitumor active tri-
azoloacridinone C-1305. In silico approach proposed here appears
very promising, allowing the identification of main metabolites of
C-1305, which are extensively metabolized as demonstrated by
electrochemical (non-enzymatic) and microsomal (enzymatic) ex-
periments performed.4. Conclusions
This work demonstrated three different strategies for the
investigation of oxidative metabolism of antitumor tri-
azoloacridinone C-1305. In particular, we presented here the first
application of electrochemical approach for generation of potential
oxidation products of the studied compound within a matrix-freeand plot of the most probable sites of C-1305 metabolism and metabolites predicted
bolized by liver P450s are marked: the darker the color and the greater the circle of
ogP are predicted values according to MetaSite software tool (version 5.1.1; Molecular
coefficient.
A. Potęga et al. / Journal of Pharmaceutical Analysis 10 (2020) 376e384 383environment. We found that a dialkylaminoalkylamino moiety was
most susceptible to electrochemical oxidation site in the C-1305
molecule. The proposed N-dealkylated, hydroxylated, and dehy-
drogenated products turned out to be typical for the processes
catalyzed by P450 isoenzymes. Next, the results achieved from EC/
ESI-MS were correlated with those from liver microsomal experi-
ments. On the one hand, each method was found to provide unique
features not identified with those of others. However, despite some
differences in the mechanisms of electrochemical and enzymatic
oxidation, the products detected after electrochemical and enzy-
matic conversion of C-1305 were generally well comparable. This
underlines the high potential of EC approach as a fast screening tool
in the prediction of metabolic transformations in drug develop-
ment. In the final step, MetaSite in silico analysis reported five top
ranked phase I metabolite structures for C-1305 liver metabolism
that helped in the interpretation of the results provided by elec-
trochemical and enzymatic approaches. The value of this strategy
consists in the possibility of gaining very useful information on the
most probable metabolites to be screened in all those cases where
the exact metabolism pathways of a compound are unknown. Ac-
cording to the above findings, the electrochemical and in silico
methods, which were shown to predict metabolism patterns, can
be used as simple and fast alternatives for metabolic (enzymatic)
assays, affording time and cost efficiency.
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